Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) - PubMed (original) (raw)
doi: 10.1097/IGC.0b013e3182070f17.
Ignace Vergote, Elizabeth Eisenhauer, Eric Pujade-Lauraine, Michael Quinn, Tate Thigpen, Andreas du Bois, Gunnar Kristensen, Anders Jakobsen, Satoru Sagae, Kathryn Greven, Mahesh Parmar, Michael Friedlander, Andres Cervantes, Jan Vermorken; Gynecological Cancer Intergroup
Affiliations
- PMID: 21270624
- DOI: 10.1097/IGC.0b013e3182070f17
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al. Int J Gynecol Cancer. 2011 Feb.
Abstract
The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well as the criteria to define response to treatment in recurrent disease using the serum marker CA 125 and has specified the situations where these criteria should be used. However, the publications did not include detailed definitions, nor were they written to accommodate the new version of Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1) now available. Thus, we recommend that the definitions described later in detail are incorporated into clinical trial protocols to maintain consistency. The criteria for defining progression are now acceptable in clinical trials of recurrent disease as they have since been validated (Pujade-Lauraine, personal communication, 2010). The GCIG requests that data from all clinical trials using these definitions are made available to GCIG trial centers so that continual validation and improvement can be accomplished. These definitions were developed from analyzing patients receiving cytotoxic chemotherapy and have not yet been validated in patients receiving molecular targeting agents.
Similar articles
- Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ. Rustin GJ. J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s. doi: 10.1200/JCO.2003.01.223. J Clin Oncol. 2003. PMID: 12743133 Review. - Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Randall LM, et al. Gynecol Oncol. 2012 Mar;124(3):563-8. doi: 10.1016/j.ygyno.2011.11.035. Epub 2011 Dec 1. Gynecol Oncol. 2012. PMID: 22138229 Free PMC article. Clinical Trial. - Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EV, Hansen HH. Gronlund B, et al. J Clin Oncol. 2004 Oct 15;22(20):4051-8. doi: 10.1200/JCO.2004.10.028. Epub 2004 Sep 13. J Clin Oncol. 2004. PMID: 15364966 - Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A, Péron J, Freyer G, You B. Colomban O, et al. Clin Cancer Res. 2019 Sep 1;25(17):5342-5350. doi: 10.1158/1078-0432.CCR-18-3335. Epub 2019 Apr 1. Clin Cancer Res. 2019. PMID: 30936122 - [Second-line chemotherapy and new drugs for ovarian carcinoma].
Priolo D, Antonelli G, Calì S, Colina P, Giuffrida D, Malaponte E, Mattina M, Parisi A, Sambataro D, Vitale F, Ferraù F. Priolo D, et al. Clin Ter. 2001 Jan-Feb;152(1):39-50. Clin Ter. 2001. PMID: 11382169 Review. Italian.
Cited by
- Developing biomarker-specific end points in lung cancer clinical trials.
Neal JW, Gainor JF, Shaw AT. Neal JW, et al. Nat Rev Clin Oncol. 2015 Mar;12(3):135-46. doi: 10.1038/nrclinonc.2014.222. Epub 2014 Dec 23. Nat Rev Clin Oncol. 2015. PMID: 25533947 Review. - No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study.
Lyu M, Lu J, Shen Y, Chen Q, Deng F, Wang J. Lyu M, et al. Front Surg. 2022 Sep 12;9:997344. doi: 10.3389/fsurg.2022.997344. eCollection 2022. Front Surg. 2022. PMID: 36171817 Free PMC article. - Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Kristeleit RS, Drew Y, Oza AM, Domchek SM, Banerjee S, Glasspool RM, Balmaña J, Chen LM, Patel MR, Burris HA, Safra T, Borrow J, Lin KK, Goble S, Maloney L, Shapira-Frommer R. Kristeleit RS, et al. Br J Cancer. 2023 Jan;128(2):255-265. doi: 10.1038/s41416-022-02022-y. Epub 2022 Dec 8. Br J Cancer. 2023. PMID: 36482193 Free PMC article. Clinical Trial. - Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.
Rubio MJ, Manzano A, de Sande LM, Estévez-García P, Gordon MDM, de Prado DS, de Aranguiz BHF, Guerra-Alia EM, Carbó-Bagué A, Romero I, Corbellas M, González-Haba A, Robles-Barraza CE, Martínez-García J, González-Martín A. Rubio MJ, et al. BMC Cancer. 2024 Jul 5;24(1):803. doi: 10.1186/s12885-024-12577-z. BMC Cancer. 2024. PMID: 38970024 Free PMC article. - Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience.
Liu Y, Cao L, Chen W, Wang J, Wang W, Liang Z. Liu Y, et al. Medicine (Baltimore). 2020 Sep 4;99(36):e22100. doi: 10.1097/MD.0000000000022100. Medicine (Baltimore). 2020. PMID: 32899091 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials